证券代码：688193 证券简称：仁度生物 公告编号：2024-045 上海仁度生物科技股份有限公司 第二届监事会第六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 三、 审议通过《关于公司<2024 年半年度募集资金存放与实际使用情况 专项报告>的议案》 上海仁度生物科技股份有限公司（以下简称"公司"）第二届监事会第六次 会议于 2024 年 8 月 29 日在公司二楼会议室以现场结合通讯的表决方式召开。 会议应到监事 3 人，实到监事 3 人，出席监事占应出席人数的 100%。公司董事、 高级管理人员列席了监事会会议。本次监事会会议的召集、召开程序符合公司 章程和有关法律、法规的要求。经与会监事审议和表决，会议形成决议如下： 一、 审议通过《关于续聘会计师事务所的议案》 表决结果：同意 3 票，反对 0 票，弃权 0 票。 本议案尚需提交股东大会审议。 具体内容详见本公司 2024 年 8 月 30 日于上海证券交易所网站 （www.sse.com.cn）披露的《关于续聘 2024 年度会计师事务所的 ...

Dividend Distribution - The company plans to distribute a cash dividend of 1.00 yuan per 10 shares, totaling approximately 3,870,857.20 yuan, which represents 89.38% of the net profit attributable to shareholders for the reporting period[5]. - The company does not have any special arrangements for corporate governance[7]. - The company has not implemented any other forms of profit distribution, such as capital reserve transfers or stock dividends, in this profit distribution plan[5]. - The company commits to a cash dividend policy, prioritizing cash dividends while ensuring long-term interests and sustainable development[88]. - The cash dividend ratio will be at least 80% for mature stages without major capital expenditures, 40% with major expenditures, and 20% for growth stages with major expenditures[88]. - The company will conduct annual dividends, with the possibility of mid-term dividends based on current profitability and cash flow[88]. Financial Performance - The company's operating revenue for the first half of 2024 was ¥86,680,181.82, representing an increase of 8.31% compared to ¥80,029,969.73 in the same period last year[17]. - The net profit attributable to shareholders of the listed company was ¥4,330,811.17, a significant recovery from a loss of ¥10,192,633.27 in the previous year[17]. - The net cash flow from operating activities was ¥10,458,030.35, improving from a negative cash flow of ¥13,947,402.37 in the same period last year[17]. - The total assets at the end of the reporting period were ¥1,021,502,138.11, down 3.15% from ¥1,054,715,696.08 at the end of the previous year[17]. - The net assets attributable to shareholders of the listed company decreased by 2.51% to ¥938,619,899.39 from ¥962,741,641.49 at the end of the previous year[17]. - The company achieved a net profit attributable to shareholders of 4.33 million yuan, an increase of 14.52 million yuan compared to the same period last year[18]. - Total operating revenue increased by 8.31% year-on-year, driven by strong sales growth in respiratory products[19]. - The company reported a total comprehensive income of RMB 9,970,669.76 for the first half of 2024, compared to a total comprehensive loss of RMB 5,869,665.10 in the previous year[136]. Research and Development - The company has invested 23.86% of its operating revenue in R&D, reflecting an increase of 0.62 percentage points year-on-year[18]. - The company holds a total of 63 patents, including 37 invention patents and 26 utility model patents[23]. - The company has obtained 20 CE certifications and 32 domestic medical device registration certificates, including 15 Class III medical device registration certificates[23]. - The company has developed a complete molecular diagnostic industry chain, including a patented RNA real-time fluorescence isothermal amplification detection technology platform[22]. - The company’s core self-produced enzyme industrial production technology has been established, enabling large-scale and high-purity production of raw material enzymes[33]. - The total R&D investment for the period was approximately ¥20.68 million, an increase of 11.19% compared to ¥18.60 million in the same period last year[38]. - The company is focusing on RNA constant temperature amplification technology, which enhances specificity and sensitivity in pathogen detection compared to DNA diagnostics[44]. Market Expansion and Strategy - The company is focusing on expanding its market presence and developing new technologies in RNA molecular diagnostics, particularly in the infection field[12]. - The company is actively pursuing new strategies for market expansion and product development to enhance its competitive position in the industry[12]. - The company achieved a significant milestone by obtaining 32 domestic medical device registration certificates, including 15 Class III and 17 Class I medical device certificates[37]. - The company is enhancing its organizational capabilities by optimizing personnel structure and attracting top talent to support international and domestic market expansion[51]. - The company focuses on expanding its market presence both domestically and internationally, enhancing its sales channels and academic promotion efforts[50]. Operational Risks and Governance - The company has outlined various operational risks and corresponding mitigation measures in the report[3]. - There are no non-operational fund occupations by controlling shareholders or related parties[6]. - The board of directors has confirmed the authenticity, accuracy, and completeness of the semi-annual report[2]. - The company has committed to long-term effective measures to address related party transactions and competition issues[76]. - The company has a long-term effective commitment to dividend distribution[76]. Compliance and Regulatory Matters - The company is committed to maintaining compliance with regulatory standards, including obtaining EU CE certification for its products[12]. - The company guarantees the authenticity, accuracy, and completeness of the prospectus and all application documents, assuming legal responsibility for any false records or misleading statements[89]. - The company will comply with all relevant laws and regulations regarding shareholding and related party transactions[80]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period[104]. - The company has not provided any guarantees that violate regulations during the reporting period[104]. Shareholder Commitments and Lock-up Periods - The controlling shareholder has pledged to minimize and regulate related party transactions to ensure fairness and independence[78]. - The company has established a lock-up period of 36 months for shares held by the controlling shareholder, with specific conditions for extension based on stock performance[79]. - If the company's stock price falls below the issue price for 20 consecutive trading days, the lock-up period will automatically extend by 6 months[79]. - Major shareholders and their affiliates commit to not transferring or managing shares held before the IPO for 36 months[84]. - The company will ensure that any share reductions by the controlling shareholder will not undermine its operational stability[80]. Financial Management and Cash Flow - The company's cash and cash equivalents decreased by 60.29% to 242,029,282.79 RMB due to increased investments in financial products[63]. - The total amount of financial assets at fair value increased by 788.33% to 446,032,291.66 RMB, primarily from purchasing more financial products[65]. - The company reported a cash outflow from financing activities of CNY 32,111,709.49, compared to CNY 6,360,045.48 in the first half of 2023, indicating a significant increase in cash outflow[139]. - The company received CNY 450,000,000.00 from investment recoveries, a substantial increase from CNY 168,388,888.89 in the same period last year, representing a growth of 167.5%[141]. - The company will strengthen internal controls and budget management to effectively manage operational risks and improve financial efficiency[98]. Legal and Regulatory Compliance - The company has not received any penalties or corrective actions related to violations of laws or regulations during the reporting period[105]. - The company and its controlling shareholders have not failed to fulfill obligations determined by effective legal documents during the reporting period[105]. - The company commits to taking measures if it fails to fulfill public commitments, including public apologies and compensation to investors for any losses incurred[103]. - The company will publicly explain any failure to adhere to these commitments and apologize to shareholders[84]. Accounting and Financial Reporting - The financial statements are prepared in accordance with the accounting standards issued by the Ministry of Finance, ensuring a true and complete reflection of the company's financial status and operating results[157]. - The company follows a 12-month operating cycle, with its accounting year running from January 1 to December 31[158][159]. - The company’s financial statements are based on the assumption of going concern, indicating that it will continue its operations for the foreseeable future[155]. - The company recognizes its share of assets and liabilities in joint operations and accounts for income and expenses accordingly[166]. - The company applies the effective interest method for calculating interest on financial assets measured at amortized cost, with gains or losses recognized upon disposal[172].

证券代码：688193 证券简称：仁度生物 公告编号：2024-041 上海仁度生物科技股份有限公司 关于股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/2/23 | | --- | --- | | 回购方案实施期限 | 第二届董事会第三次会议审议通过后 6 个月 | | 预计回购金额 | 元~50,000,000 元 25,000,000 | | 回购价格上限 | 53.31 元/股 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 实际回购股数 | 1,291,428 股 | | 实际回购股数占总股本比例 | 3.2286% | | 实际回购金额 | 元 35,648,734.79 | | 实际回购价格区间 | 24.44 元/股~30.55 元/股 | 一、 回购审批情况和回购方案内容 公司于 2024 年 2 月 18 日召开第二届董事会第三次会 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/2/23 | | --- | --- | | 回购方案实施期限 | 第二届董事会第三次会议审议通过后 6 个月 | | 预计回购金额 | 元~50,000,000 元 25,000,000 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 股 1,291,428 | | 累计已回购股数占总股本比例 | 3.2286% | | 累计已回购金额 | 35,648,734.79 元 | | 实际回购价格区间 | 24.44 元/股~30.55 元/股 | 一、 回购股份的基本情况 证券代码：688193 证券简称：仁度生物 公告编号：2024-040 上海仁度生物科技股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 二、 回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号— ...

上海证券交易所 纪律处分决定书 〔2024〕137 号 关于对上海仁度生物科技股份有限公司及有关 责任人予以通报批评的决定 当事人： 蔡廷江，上海仁度生物科技股份有限公司时任财务总监兼董 -1- ──────────────────────── 上海仁度生物科技股份有限公司，A 股证券简称：仁度生物， A 股证券代码：688193； 居金良，上海仁度生物科技股份有限公司时任董事长； 于明辉，上海仁度生物科技股份有限公司时任总经理； 对于上述纪律处分事项，公司及有关责任人均提出异议称， 事会秘书。 一、上市公司及相关主体违规情况 经查明，2024 年 1 月 31 日，上海仁度生物科技股份有限公 司（以下简称公司）披露《2023 年年度业绩预告》，预计 2023 年年度实现归属于母公司所有者的净利润（以下简称归母净利润） 为 230 万元到 340 万元。2024 年 2 月 28 日，公司披露《2023 年 年度业绩快报公告》，预计 2023 年度实现营业利润为 7.51 万元， 利润总额为-60.46 万元，归母净利润为 318.22 万元，基本每股收 益为 0.08 元，加权平均净资产收益率为 0.33% ...

证券代码：688193 证券简称：仁度生物 公告编号：2024-039 上海仁度生物科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 关于以集中竞价交易方式回购公司股份比例 达到总股本 3%暨回购进展的公告 二、 回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号—回购股份》等相关规定，回购股份占上市公司总股本的比例每增加 1%的，应 当在事实发生之日起 3 个交易日内予以公告。现将公司回购股份进展情况公告如 下： 截至 2024 年 7 月 24 日，公司通过上海证券交易所交易系统以集中竞价交易 方式累计回购公司股份 1,251,539 股，占公司总股本 40,000,000 股的比例为 3.1288%， 回购成交的最高价为 30.55 元/股，最低价为 24.44 元/股，已支付的资金总额为人 民币 34,656,300.25 元（不含印花税、交易佣金等交易费用）。 上述股份回购符合法律法规的规定及公司回购股份方案的要求。 三、 其他事项 重要内容提示： | 回购 ...

证券代码：688193 证券简称：仁度生物 公告编号：2024-038 上海仁度生物科技股份有限公司 关于公司及相关当事人受到上海证券交易所 通报批评的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海仁度生物科技股份有限公司（以下简称"公司"或"仁度生物"）于 2024 年 7 月 12 日收到上海证券交易所（以下简称"上交所"）下发的《关于对上海 仁度生物科技股份有限公司及有关责任人予以通报批评的决定》（〔2024〕137 号，以下简称"《处分决定》"），上交所对仁度生物及公司董事长居金良先生、 总经理于明辉女士、时任财务总监兼董事会秘书蔡廷江先生给予通报批评的处分。 公司已将《处分决定》转交上述各相关当事人，《处分决定》具体内容如下： 上海仁度生物科技股份有限公司，A 股证券简称：仁度生物，A 股证券代码： 688193； 居金良，上海仁度生物科技股份有限公司时任董事长； 于明辉，上海仁度生物科技股份有限公司时任总经理； 蔡廷江，上海仁度生物科技股份有限公司时任财务总监兼董事会秘书。 一、上市公司及相关主体违 ...

证券代码：688193 证券简称：仁度生物 公告编号：2024-037 上海仁度生物科技股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 二、 回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号—回购股份》等相关规定，公司应在每个月的前 3 个交易日内公告截至上月末 的回购进展情况。现将公司回购股份进展情况公告如下： 截至 2024 年 6 月 30 日，公司通过上海证券交易所交易系统以集中竞价交易 方式累计回购公司股份 804,169 股，占公司总股本 40,000,000 股的比例为 2.0104%， 回购成交的最高价为 30.55 元/股，最低价为 26.31 元/股，支付的资金总额为人民 币 23,371,319.49 元（不含印花税、交易佣金等交易费用）。 上述股份回购符合法律法规的规定及公司回购股份方案的要求。 三、 其他事项 重要内容提示： | 回购方案首次披露日 | 2024/2/23 | | --- | -- ...

证券代码：688193 证券简称：仁度生物 公告编号：2024-036 上海仁度生物科技股份有限公司 第二届监事会第五次会议决议公告 公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 上海仁度生物科技股份有限公司（以下简称"公司"）第二届监事会第五次 会议于 2024 年 6 月 24 日在公司二楼会议室以现场结合通讯的表决方式召开。 会议应到监事 3 人，实到监事 3 人，出席监事占应出席人数的 100%。本次监事 会会议的召集、召开程序符合公司章程和有关法律、法规的要求。经与会监事 审议和表决，会议形成决议如下： 一、 审议通过《关于增加 2024 年度日常关联交易预计的议案》 公司监事会一致认为：公司本次增加 2024 年度日常关联交易额度预计是为 了满足日常生产经营的需要，关联交易定价依据公平、合理，没有违反公开、 公平、公正的原则，不存在损害公司和中小股东的利益的行为，不会对公司独 立性产生影响，公司主营业务不会因此类交易而对关联方形成依赖，其审议和 决策程序符合相关法律法规的规定。因此，监事会一致同意公司本次增加 ...

证券代码：688193 证券简称：仁度生物 公告编号：2024-035 上海仁度生物科技股份有限公司 关于增加 2024 年度日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 是否需要提交股东大会审议：否 日常关联交易对上市公司的影响：本次增加2024年度日常关联交易预计 属于与日常经营相关的关联交易，以市场公允价格为定价原则，不影响公司的独 立性，不存在损害公司及公司股东利益的情形，公司不会因该关联交易对关联人 产生依赖。 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 上海仁度生物科技股份有限公司（以下简称"公司"）于2024年6月24日召开 第二届董事会第七次会议审议通过了《关于增加2024年度日常关联交易预计的议 案》，表决结果为：赞成7票，无反对票，无弃权票。 本次日常关联交易为公司的子公司泰州智量医学检验有限公司（以下简称 "泰州智量"）向常州瑞鸿医院有限公司实验室提供医学检验和试剂销售服务， 预计增加金额为500万元。据《上海证券交易所科创板股票上市规则》《 ...